#### 16.1.5.1 SPONSOR

### CLINICAL STUDY REPORT APPROVAL FORM

PROTOCOL NUMBER:	C4591001
REPORT TITLE:	Interim Report – 6 Month Update: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
AUTHOR:	Dzung Nguyen

I have reviewed this clinical study report, which is from its definitive source and final in content. I confirm that it is a complete and accurate representation of the relevant data and statistical analyses for this report.

Known deviations in the study did not impact overall compliance with Good Clinical Practice and local regulations.

Organization/Institution: BioNTech SE

Name/Position: Ugur Sahin, MD, Chief Executive Officer

Signature:

29.04.2021 Date:

### 16.1.5.1 SPONSOR AGENT

## CLINICAL STUDY REPORT APPROVAL FORM

<b>PROTOCOL NUMBER:</b>	C4591001
REPORT TITLE:	Interim Report – 6 Month Update: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
AUTHOR:	Dzung Nguyen

I have reviewed this clinical study report, which is from its definitive source and final in content. I confirm that it is a complete and accurate representation of the relevant data and statistical analyses for this report.

Known deviations in the study did not impact overall compliance with Good Clinical Practice and local regulations.

STATISTICS LINE HEAD: Kenneth Koury, PhD

CLINICAL LEAD: John L. Perez, MD, MBA, MA

# **Document Approval Record**

Document Name:	16.1.5.1 - Sponsor Agent	
Document Title:	C4591001 Additional Analysis	
Signed By:	Date(GMT)	Signing Capacity
<b>Signed By:</b> Perez, John	Date(GMT) 29-Apr-2021 12:29:21	Signing Capacity Final Approval